Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

A double-blind, randomized, multicenter, placebo-controlled, parallel-group, study comparing the efficacy and safety of 0.50 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis.
Brief Description  
The purpose of this study is to evaluate the effectiveness of FTY720 in delaying MS disability progression in the absence of relapses in comparison to placebo in patients with primary progressive multiple sclerosis.
Who may be Eligible  
The study population will consist of a representative group of patients with primary progressive multiple sclerosis, male or female ages 25 to 65, who have had MS from 2 to 10 years prior to study start.
MS - Multiple Sclerosis
IRB Number  
Principal Investigator  
Kaufman, Michael

For More Information, Contact  Rita  , Rouse
Phone:  (704) 446-1902  Fax:  (704) 446-6802  
Email:  rita.rouse@carolinashealthcare.org
Address:1010 Edgehill Road North Charlotte, NC 28207